65 stories mentioning BSXUpdated 11h ago
Every FINWIRES story that references BSX, newest first.
Health care stocks declined late Wednesday afternoon, with the NYSE Health Care Index down 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) fell 1.5%.In corporate news, Boston Scientific (BSX) shares fell 3.6% after Daiwa Securities downgraded the stock to neutral from outperform, and lowered its price target to $60 per share from $83 earlier.
Boston Scientific (BSX) shares fell 3.4% in Wednesday afternoon trading after Daiwa Securities downgraded the stock to neutral from outperform, and lowered its price target to $60 per share from $83 earlier.Trading volume stood at about 12.9 million shares, compared with a daily average of over 17.6 million.Price: $56.49, Change: $-1.96, Percent Change: -3.35%
Boston Scientific (BSX) has an average rating of buy and mean price target of $85.84, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Boston Scientific (BSX) has an average rating of Buy and mean price target of $86.58, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $61.33, Change: $-0.74, Percent Change: -1.19%
Boston Scientific (BSX) posted Q1 sales and earnings per share beats alongside a "prudent" guidance cut, with Q2 expected to be the trough quarter, RBC Capital Markets said in a note Wednesday.The analysts said management lowered 2026 organic growth outlook to 6.5% to 8% due to "unanticipated headwinds" and "changing business patterns," though many investors already expected a reset, including those who believed the company could make the numbers to reset the base.The analysts called Q1 a "clearing event," with Boston Scientific reporting Electrophysiology growing 21.7% year-over-year on an organic basis versus 18.5% consensus, while Watchman grew 18.8% versus 21.5% consensus, broadly in line with expectations."Looking ahead, we view Q2 as a trough quarter (guided 5% to 7%) with improving growth thereafter aided by new products, improvement in base businesses, and Watchman growth in low double digits. We would be buyers at current valuations," the analysts said.RBC reiterated its outperform rating on Boston Scientific and adjusted its price target to $100 from $105.Price: $65.76, Change: $+0.89, Percent Change: +1.37%
Boston Scientific (BSX) has an average rating of Buy and mean price target of $87.23, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $65.88, Change: $+1.01, Percent Change: +1.55%
Boston Scientific (BSX) has an average rating of buy and mean price target of $87.23, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $66.55, Change: $+1.68, Percent Change: +2.59%
The Nasdaq Composite and the S&P 500 hit record highs on Wednesday as upbeat corporate results overshadowed a rise in oil prices following Iran's seizure of two container ships in the Strait of Hormuz.The Nasdaq rose 1.6% to 24,657.6, while the S&P 500 climbed 1.1% to 7,137.9, both finishing at all-time highs after a two-day losing streak. The Dow Jones Industrial Average added 0.7% to 49,490.Most sectors were in the green, led by technology's 2.3% advance, while real estate saw the steepest decline.Boeing's (BA) first-quarter loss unexpectedly narrowed as commercial aircraft deliveries rose, while the plane maker reported a smaller cash burn year over year. The stock jumped 5.5%, the best performer on the Dow.Boston Scientific (BSX) shares surged 9%, the third-biggest gain on the S&P 500. The medical device supplier's first-quarter results exceeded Wall Street's estimates, but it lowered its full-year guidance.Philip Morris International (PM) reported first-quarter results above market estimates, while lowering its full-year earnings outlook. The cigarette and vape maker's shares jumped 7%.A number of tech stocks climbed, with Micron (MU) up 8.5%, among the biggest gains on the S&P 500. Apple (AAPL) rose 2.6%, the second-best performer on the Dow. Microsoft (MSFT) and Salesforce (CRM) also rose.West Texas Intermediate crude rose 3.3% to $92.58 per barrel in Wednesday late-afternoon trade, while Brent jumped 3% to $101.44.Iran said it seized two container ships attempting to cross the Strait of Hormuz, a key oil chokepoint. US President Donald Trump extended a ceasefire with Tehran late Tuesday, though he said the naval blockade of Iranian ports would continue.The status of a second round of peace talks between the US and Iran remained unclear.Trump does not consider Iran's claim that it seized two ships as a violation of the ceasefire, CNN reported, citing White House Press Secretary Karoline Leavitt.Tehran welcomes dialogue, but "breach of commitments, blockade and threats are main obstacles to genuine negotiations," Iranian President Masoud Pezeshkian said in a post on X on Wednesday."Oil prices continue to whipsaw as traders respond to a confusing and often contradictory flow of headlines, underscoring the deep mistrust between Tehran and Washington," Saxo Bank Head of Commodity Strategy Ole Hansen said in a report on Wednesday.US Treasury yields were mixed, with the 10-year rate little changed at 4.31% and the two-year rate up 2.7 basis points at 3.81%.Gold was up 0.9% at $4,759.60 per troy ounce, while silver gained 1.7% to $77.75 per ounce.
Health care stocks were mixed late Wednesday afternoon, with the NYSE Health Care Index down 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.1%.The iShares Biotechnology ETF (IBB) eased 0.1%.In corporate news, Biogen (BIIB) shares rose 2.2% after UBS upgraded the biotechnology company's stock to buy from neutral and boosted its price target to $225 per share from $185.Boston Scientific (BSX) shares jumped 8.3% after the company reported Q1 results exceeded Wall Street's estimates.Intuitive Surgical (ISRG) shares climbed 7% after the company lifted the full-year procedure growth outlook of its Da Vinci robotic surgery system and reported better-than-expected Q1 results.Merck (MRK), Germany's Merck KGaA and Japan's Ono Pharmaceutical expressed interest in Inhibrx Biosciences' (INBX) experimental cancer medicine that may be valued at more than $8 billion, Reuters reported. Merck shares rose 0.4%, and Inhibrx surged 35%.
Boston Scientific (BSX) has an average rating of buy and mean price target of $95.97, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $64.97, Change: $+5.45, Percent Change: +9.16%
US benchmark equity indexes were higher intraday following a batch of upbeat corporate results, while oil prices rose after Iran seized two container ships in the Strait of Hormuz.The Nasdaq Composite was up 1.3% at 24,577.8 after midday Wednesday, while the S&P 500 rose 0.8% to 7,121.3. The Dow Jones Industrial Average climbed 0.6% to 49,444. Among sectors, tech paced the gainers with a 2.1% advance, while real estate saw the steepest decline.Boeing's (BA) first-quarter loss unexpectedly narrowed as commercial aircraft deliveries rose, while the plane maker reported a smaller cash burn year over year. The stock was up 5.4% intraday, the best performer on the Dow.Boston Scientific (BSX) shares were advancing by 8.9%, the third-biggest gain on the S&P 500. The medical device supplier's first-quarter results exceeded Wall Street's estimates, but it lowered its full-year guidance.Philip Morris International (PM) reported first-quarter results above market estimates, while lowering its full-year earnings outlook. The cigarette and vape maker's shares rose 6.9%.A number of major tech stocks were advancing intraday, with Micron (MU) up 7.7%, among the best performers on the S&P 500. Apple (AAPL) rose 2.6%, the second-biggest gain on the Dow. Microsoft (MSFT) and Salesforce (CRM) were also higher.Tesla (TSLA), International Business Machines (IBM), and Texas Instruments (TXN) are scheduled to report results after the closing bell Wednesday. IBM shares were down 1.9% intraday, the steepest decline on the Dow.West Texas Intermediate crude rose 3.7% to $92.94 per barrel, while Brent jumped 3.3% to $101.76.Iran said it seized two container ships attempting to cross the Strait of Hormuz, a key oil chokepoint. US President Donald Trump extended a ceasefire with Tehran late Tuesday, though he said the naval blockade of Iranian ports would continue.The status of a second round of peace talks between the US and Iran remained unclear."Oil prices continue to whipsaw as traders respond to a confusing and often contradictory flow of headlines, underscoring the deep mistrust between Tehran and Washington," Saxo Bank Head of Commodity Strategy Ole Hansen said in a report on Wednesday.US Treasury yields were mixed intraday, with the 10-year rate little changed at 4.31% and the two-year rate up 2.5 basis points at 3.80%.Gold was up 0.7% at $4,753 per troy ounce, while silver gained 1.8% to $77.90 per ounce.
Health care stocks edged up Wednesday afternoon with the NYSE Health Care Index little changed, paring earlier gains, and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.2%.The iShares Biotechnology ETF (IBB) rose 0.2%.In corporate news, Boston Scientific (BSX) shares jumped 9.1% after the company reported Q1 results exceeded Wall Street's estimates.Intuitive Surgical (ISRG) shares climbed 7.7% after the company lifted the full-year procedure growth outlook of its Da Vinci robotic surgery system and reported better-than-expected Q1 results.Merck (MRK), Germany's Merck KGaA and Japan's Ono Pharmaceutical expressed interest in Inhibrx Biosciences' (INBX) experimental cancer medicine that may be valued at more than $8 billion, Reuters reported. Merck shares rose 0.2%, and Inhibrx surged 42%.
Health care stocks edged higher Wednesday afternoon, with the NYSE Health Care Index increasing 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.3%.The iShares Biotechnology ETF (IBB) was up 0.1%.In corporate news, Boston Scientific (BSX) shares jumped nearly 9% after its Q1 results exceeded Wall Street's estimates.
Boston Scientific (BSX) has an average rating of buy and mean price target of $95.97, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $64.95, Change: $+5.42, Percent Change: +9.11%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After the solid Q1 results announcement this morning amid a challenging operating environment, we retain our target at $100, based on 24.8x our 2027 EPS estimate, a discount to its five-year historical forward P/E average of 27.5x. We lower our 2026 EPS view to $3.40 from $3.49 as we adjust our top- and bottom-line forecasts to take into account a softer outlook in the Electrophysiology, Watchman, and Urology businesses. We maintain our 2027 EPS estimate at $4.04. We continue to view the large $14.5 billion pending acquisition of Penumbra (a leading thrombectomy firm focused on innovative technologies to treat challenging medical conditions), which is expected to close in the second half of 2026, as strategically compelling for BSX and potentially key to accelerating its growth. Despite near-term challenges (supply chain disruptions, increased competition), we remain confident in the company's long-term growth prospects, supported by a strong product pipeline and strategic investments.
All three major US stock indexes were up in late-morning trading Wednesday following reports of Iranian attacks on vessels in the Strait of Hormuz and President Donald Trump's extension of the ceasefire between the warring nations.In company news, GE Vernova (GEV) reported Q1 earnings Wednesday of $17.44 per share, up from $0.91 a year earlier. Total Q1 revenue was $9.34 billion, up from $8.03 billion a year ago and above the FactSet consensus analyst estimate of $9.25 billion. For 2026, the company said it expects revenue of about $44.5 billion to $45.5 billion, up from its previous outlook of $44 billion to $45 billion and compared to the FactSet consensus of $44.66 billion. GE Vernova shares were up 12.4% around midday.Vertiv (VRT) reported Q1 adjusted earnings Wednesday of $1.17 per diluted share, up from $0.64 a year earlier and above the FactSet consensus of $1.00. First-quarter revenue was $2.65 billion, up from $2.04 billion a year ago and above the FactSet consensus of $2.64 billion. For Q2, the company said it expects adjusted EPS of $1.37 to $1.43 on revenue of $3.25 billion to $3.45 billion. Analysts polled by FactSet expect $1.43 and $3.40 billion, respectively. For full-year 2026, Vertiv said it expects adjusted EPS of $6.30 to $6.40, up from its previous outlook of $5.97 to $6.07 and above the FactSet consensus of $6.12. Vertiv expects full-year revenue to be $13.50 billion to $14.00 billion, up from its previous guidance of $13.25 billion to $13.75 billion and compared to the FactSet consensus of $13.63 billion. Vertiv shares were down 2.6%.Merck (MRK), Germany's Merck KGaA and Japan's Ono Pharmaceutical have expressed interest in Inhibrx Biosciences' (INBX) experimental cancer medicine that could be valued at over $8 billion, Reuters reported Wednesday, citing people familiar with the matter. Merck shares were down 0.2%, while Inhibrx shares were up 31.9%.Boeing (BA) reported a Q1 core loss Wednesday of $0.20 per share, narrowing from a loss of $0.49 a year earlier and compared to the FactSet consensus estimate of a loss of $0.68. First-quarter revenue was $22.22 billion, up from $19.50 billion a year ago and above the FactSet consensus of $21.85 billion. Cash outflow for the quarter was $1.45 billion, narrowing from $2.29 billion a year ago, and the company said Q1 deliveries increased 10% to 143 planes. Boeing shares were up 5.4%.Alphabet's (GOOG, GOOGL) Google Cloud is launching a $750 million fund to help consulting firms like Accenture (ACN), McKinsey and Deloitte get their clients to use agentic AI software, Bloomberg reported Wednesday, citing an emailed statement and an interview with a company official. Alphabet's Class C and Class A shares were up 1.5% and 1.6%, respectively. Accenture shares were down 1.9%.Philip Morris International (PM) reported Q1 adjusted earnings Wednesday of $1.96 per diluted share, up from $1.69 a year earlier and above the FactSet consensus of $1.83. Net Q1 revenue was $10.15 billion, up from $9.30 billion ay ear ago and above the FactSet consensus of $9.91 billion. For Q2, Philip Morris said it expects adjusted EPS of $2.02 to $2.07, below the FactSet consensus of $2.12. For full-year 2026, the company said it expects adjusted EPS of $8.36 to $8.51, compared to the FactSet consensus of $8.38. Philip Morris shares were up 7%.Boston Scientific (BSX) reported Q1 adjusted earnings Wednesday of $0.80 per share, up from $0.75 a year earlier and above the FactSet consensus of $0.79. First-quarter net sales were $5.20 billion, up from $4.66 billion a year ago and above the FactSet consensus of $5.17 billion. For Q2, Boston Scientific said it expects adjusted EPS of $0.82 to $0.84 and net sales growth of 5.5% to 7.5%. Analysts polled by FactSet expect adjusted EPS of $0.86. For full-year 2026, the company said it expects adjusted EPS of $3.34 to $3.41, down from its prior outlook of $3.43 to $3.49 and below the FactSet consensus of $3.45. Full-year net sales are now expected to grow about 7.0% to 8.5%, down from the company's previous guidance of 10.5% to 11.5% growth. Shares of the company were up 8.4%.AT&T (T) reported Q1 earnings Wednesday of $0.54 per diluted share, down from $0.61 a year earlier and below the FactSet consensus of $0.55. First-quarter operating revenue was $31.51 billion, up from $30.63 billion a year ago and above the FactSet consensus of $31.25 billion. AT&T shares were down 1.8%.Price: $1119.35, Change: $+128.05, Percent Change: +12.92%
Boston Scientific's (BSX) first-quarter results exceeded Wall Street's estimates, while the medical device supplier lowered its full-year guidance on Wednesday.For the March quarter, adjusted earnings grew to $0.80 from $0.75 a year earlier, while net sales rose nearly 12% to $5.20 billion. The FactSet-polled consensus estimates are for $0.79 and $5.17 billion, respectively.First-quarter sales in the cardiovascular business surged 13.5% year over year to $3.50 billion. The MedSurg division grew 7.8% to $1.70 billion with double-digit gains in neuromodulation. The company logged revenue growth across all regions, led by a 19% increase in the Latin America and Caribbean.Shares of Boston Scientific were up 9.2% in Wednesday trade. The stock has plunged 32% so far this year.The company lowered its 2026 net sales growth outlook to between 7% and 8.5% from a 10.5% to 11.5% increase previously expected. The company now estimates adjusted EPS of $3.34 to $3.41, down from the prior guidance of $3.43 to $3.49. The market expects $22.24 billion in full-year revenue and $3.45 of EPS.For the second quarter, the company guided adjusted EPS at $0.82 to $0.84 on sales growth of 5.5% to 7.5%. Analysts expect EPS of $0.86 and sales of $5.55 billion."Second quarter is our toughest quarter of the year," Chief Executive Mike Mahoney said on an earnings call, according to a FactSet transcript.Price: $64.77, Change: $+5.25, Percent Change: +8.82%
Boston Scientific (BSX) has an average rating of Buy and mean price target of $96.45, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $64.59, Change: $+5.07, Percent Change: +8.52%
Health care stocks were edging higher premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.4% and the iShares Biotechnology ETF (IBB) 0.3% higher.Boston Scientific (BSX) shares were up more than 5% after the company reported higher Q1 adjusted earnings and net sales.Merck (MRK), Germany's Merck KGaA and Japan's Ono Pharmaceutical have expressed interest in Inhibrx Biosciences' (INBX) experimental cancer medicine that could be valued at more than $8 billion, Reuters reported, citing people familiar with the matter. Inhibrx Biosciences stock was up more than 48% pre-bell.Healthcare Services Group (HCSG) shares were up more than 22% after the company reported higher Q1 earnings and revenue.
Health care stocks were edging higher premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.5% and the iShares Biotechnology ETF (IBB) 0.3% higher.Boston Scientific (BSX) shares were up more than 5% after the company reported higher Q1 adjusted earnings and net sales.
Showing 41-60 of 65
